Application of immune checkpoint inhibitors in non-small cell lung cancer with EGFR mutant

doi:10.3760/cma.j.cn371439-20200209-00078

Abstract

Abstract:

Epidermal growth factor receptor (EGFR) gene is one of the most common driving genes in non-small cell lung cancer patients, and immune checkpoint inhibitors (ICIs) have been controversial in the clinical application of non-small cell lung cancer with EGFR mutant. The expression abundance of programmed death ligand 1 (PD-L1) is an important predictor to guide the application of ICIs, and EGFR mutations may affect PD-L1 expression in tumor cells. Recent clinical studies have pointed out that the single drug of ICIs is not effective in patients with EGFR mutation, however, the combination of ICIs combined with chemotherapy and the four drugs proposed in the IMpower150 trial show good clinical benefits. In addition, the safety of ICIs and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) combination model needs to be further clarified.

Key words: Immunotherapy, Receptor,epidermal growth factor, Carcinoma,non-small-cell lung

Xu Zexi, Zhang Huibo, Jin Yao, Peng Min. Application of immune checkpoint inhibitors in non-small cell lung cancer with EGFR mutant[J]. Journal of International Oncology, 2020, 47(9): 560-564.

References 44

[1]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018,68(6):394-424. DOI: 10.3322/caac.21492. doi: 10.3322/caac.21492 pmid: 30207593
[2]	Osmani L, Askin F, Gabrielson E, et al. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): moving from targeted therapy to immunotherapy[J]. Semin Cancer Biol, 2018,52(Pt 1):103-109. DOI: 10.1016/j.semcancer.2017.11.019. doi: 10.1016/j.semcancer.2017.11.019 pmid: 29183778
[3]	Walters S, Maringe C, Coleman MP, et al. Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004-2007[J]. Thorax, 2013,68(6):551-564. DOI: 10.1136/thoraxjnl-2012-202297. pmid: 23399908
[4]	Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer[J]. N Engl J Med, 2018,378(2):113-125. DOI: 10.1056/NEJMoa1713137. doi: 10.1056/NEJMoa1713137 pmid: 29151359
[5]	Stella GM, Luisetti M, Pozzi E, et al. Oncogenes in non-small-cell lung cancer: emerging connections and novel therapeutic dynamics[J]. Lancet Respir Med, 2013,1(3):251-261. DOI: 10.1016/S2213-2600(13)70009-2. doi: 10.1016/S2213-2600(13)70009-2 pmid: 24429131
[6]	Santoni-Rugiu E, Melchior LC, Urbanska EM, et al. Intrinsic resis-tance to EGFR-tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: differences and similarities with acquired resistance[J]. Cancers (Basel), 2019,11(7):923. DOI: 10.3390/cancers11070923. doi: 10.3390/cancers11070923
[7]	Raju S, Joseph R, Sehgal S. Review of checkpoint immunotherapy for the management of non-small cell lung cancer[J]. Immunotargets Ther, 2018,7:63-75. DOI: 10.2147/ITT.S125070. doi: 10.2147/ITT.S125070 pmid: 30105218
[8]	Kazandjian D, Suzman DL, Blumenthal G, et al. FDA approval summary: nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy[J]. Oncologist, 2016,21(5):634-642. DOI: 10.1634/theoncologist.2015-0507. pmid: 26984449
[9]	Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application[J]. Int Immunol, 2007,19(7):813-824. DOI: 10.1093/intimm/dxm057. doi: 10.1093/intimm/dxm057 pmid: 17606980
[10]	Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus doceta-xel in advanced squamous-cell non-small-cell lung cancer[J]. N Engl J Med, 2015,373(2):123-135. DOI: 10.1056/NEJMoa1504627. doi: 10.1056/NEJMoa1504627 pmid: 26028407
[11]	Mu CY, Huang JA, Chen Y, et al. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation[J]. Med Oncol, 2011,28(3):682-688. DOI: 10.1007/s12032-010-9515-2. doi: 10.1007/s12032-010-9515-2 pmid: 20373055
[12]	Akbay EA, Koyama S, Carretero J, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors[J]. Cancer Discov, 2013,3(12):1355-1363. DOI: 10.1158/2159-8290.CD-13-0310. doi: 10.1158/2159-8290.CD-13-0310 pmid: 24078774
[13]	Tang Y, Fang W, Zhang Y, et al. The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs[J]. Oncotarget, 2015,6(16):14209-14219. DOI: 10.18632/oncotarget.3694. doi: 10.18632/oncotarget.3694 pmid: 25895031
[14]	Wu J, Sun W, Wang H, et al. The correlation and overlaps between PD-L1 expression and classical genomic aberrations in Chinese lung adenocarcinoma patients: a single center case series[J]. Cancer Biol Med, 2019,16(4):811-821. DOI: 10.20892/j.issn.2095-3941.2019.0209. pmid: 31908897
[15]	Peng S, Wang R, Zhang X, et al. EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression[J]. Mol Cancer, 2019,18(1):165. DOI: 10.1186/s12943-019-1073-4. pmid: 31747941
[16]	Dong Z, Zhang J, Liu S, et al. EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer[J]. Oncoimmunology, 2017,6(11):e1356145. DOI: 10.1080/2162402X.2017.1356145. doi: 10.1080/2162402X.2017.1356145 pmid: 29147605
[17]	Lee J, Park CK, Yoon HK, et al. PD-L1 expression in ROS1-rearranged non-small cell lung cancer: a study using simultaneous genotypic screening of EGFR, ALK, and ROS1[J]. Thorac Cancer, 2019,10(1):103-110. DOI: 10.1111/1759-7714.12917. pmid: 30475455
[18]	Lee SE, Kim YJ, Sung M, et al. Association with PD-L1 expression and clinicopathological features in 1000 lung cancers: a large single-institution study of surgically resected lung cancers with a high prevalence of EGFR mutation[J]. Int J Mol Sci, 2019,20(19):4794. DOI: 10.3390/ijms20194794. doi: 10.3390/ijms20194794
[19]	Takada K, Toyokawa G, Okamoto T, et al. A comprehensive analysis of programmed cell death ligand-1 expression with the clone SP142 antibody in non-small-cell lung cancer patients[J]. Clin Lung Cancer, 2017,18(85):572-582.e1. DOI: 10.1016/j.cllc.2017.02.004. doi: 10.1016/j.cllc.2017.02.004
[20]	Takada K, Toyokawa G, Tagawa T, et al. PD-L1 expression accor-ding to the EGFR status in primary lung adenocarcinoma[J]. Lung Cancer, 2018,116:1-6. DOI: 10.1016/j.lungcan.2017.12.003. pmid: 29413045
[21]	Bai Y, Chen X, Hou L, et al. PD-L1 expression and its effect on clinical outcomes of EGFR-mutant NSCLC patients treated with EGFR-TKIs[J]. Cancer Biol Med, 2018,15(4):434-442. DOI: 10.20892/j.issn.2095-3941.2018.0223. doi: 10.20892/j.issn.2095-3941.2018.0223 pmid: 30766753
[22]	Lisberg A, Cummings A, Goldman JW, et al. A phase Ⅱ study of pembrolizumab in EGFR-mutant, PD-L1⁺ tyrosine kinase inhibitor naive patients with advanced NSCLC [J]. J Thorac Oncol, 2018,13(8):1138-1145. DOI: 10.1016/j.jtho.2018.03.035. doi: 10.1016/j.jtho.2018.03.035 pmid: 29874546
[23]	Mok T, Wu YL, Kudaba I, et al. Pembrolizumab versus chemothe-rapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a rando-mised, open-label, controlled, phase 3 trial[J]. Lancet, 2019,393(10183):1819-1830. DOI: 10.1016/S0140-6736(18)32409-7. doi: 10.1016/S0140-6736(18)32409-7 pmid: 30955977
[24]	Lee CK, Man J, Lord S, et al. Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer—a meta-analysis[J]. J Thorac Oncol, 2017,12(2):403-407. DOI: 10.1016/j.jtho.2016.10.007. doi: 10.1016/j.jtho.2016.10.007 pmid: 27765535
[25]	Lee CK, Man J, Lord S, et al. Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non-small cell lung carcinoma: a systematic review and meta-analysis[J]. JAMA Oncol, 2018,4(2):210-216. DOI: 10.1001/jamaoncol.2017.4427. doi: 10.1001/jamaoncol.2017.4427 pmid: 29270615
[26]	Garassino MC, Cho BC, Kim JH, et al. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study[J]. Lancet Oncol, 2018,19(4):521-536. DOI: 10.1016/S1470-2045(18)30144-X. doi: 10.1016/S1470-2045(18)30144-X
[27]	Rangachari D, VanderLaan PA, Costa DB. Updated correlation of 22C3-PD-L1 ≥50% expression with driver oncogene mutations and response to pembrolizumab in the kinase inhibitor-resistant setting[J]. J Thorac Oncol, 2018,13(5):e81-e83. DOI: 10.1016/j.jtho.2018.01.023. doi: 10.1016/j.jtho.2018.01.023 pmid: 29703544
[28]	Gettinger S, Horn L, Jackman D, et al. Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: results from the CA209-003 study[J]. J Clin Oncol, 2018,36(17):1675-1684. DOI: 10.1200/JCO.2017.77.0412. doi: 10.1200/JCO.2017.77.0412 pmid: 29570421
[29]	Vanmeerbeek I, Sprooten J, De Ruysscher D, et al. Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology[J]. Oncoimmunology, 2020,9(1):1703449. DOI: 10.1080/2162402X.2019.1703449. doi: 10.1080/2162402X.2019.1703449 pmid: 32002302
[30]	Liu WM, Fowler DW, Smith P, et al. Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses[J]. Br J Cancer, 2010,102(1):115-123. DOI: 10.1038/sj.bjc.6605465. pmid: 19997099
[31]	Sakai H, Takeda M, Sakai K, et al. Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion[J]. Lung Cancer, 2019,127:59-65. DOI: 10.1016/j.lungcan.2018.11.025. doi: 10.1016/j.lungcan.2018.11.025 pmid: 30642552
[32]	Zhang P, Ma Y, Lv C, et al. Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy[J]. Cancer Sci, 2016,107(11):1563-1571. DOI: 10.1111/cas.13072. pmid: 27581532
[33]	Rizvi NA, Hellmann MD, Brahmer JR, et al. Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer[J]. J Clin Oncol, 2016,34(25):2969-2979. DOI: 10.1200/JCO.2016.66.9861. doi: 10.1200/JCO.2016.66.9861 pmid: 27354481
[34]	Kanda S, Goto K, Shiraishi H, et al. Safety and efficacy of nivolu-mab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ⅰb study[J]. Ann Oncol, 2016,27(12):2242-2250. DOI: 10.1093/annonc/mdw416. pmid: 27765756
[35]	Langer CJ, Gadgeel SM, Borghaei H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study[J]. Lancet Oncol, 2016,17(11):1497-1508. DOI: 10.1016/S1470-2045(16)30498-3. doi: 10.1016/S1470-2045(16)30498-3 pmid: 27745820
[36]	Reck M, Mok TSK, Nishio M, et al. Atezolizumab plus bevacizu-mab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial[J]. Lancet Respir Med, 2019,7(5):387-401. DOI: 10.1016/S2213-2600(19)30084-0. doi: 10.1016/S2213-2600(19)30084-0 pmid: 30922878
[37]	Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC[J]. N Engl J Med, 2018,378(24):2288-2301. DOI: 10.1056/NEJMoa-1716948. pmid: 29863955
[38]	Arrieta O, Barrón F, Ramírez-Tirado LA, et al. Efficacy and safety of pembrolizumab plus docetaxel vs docetaxel alone in patients with previously treated advanced non-small cell lung cancer: the PROLUNG phase 2 randomized clinical trial[J]. JAMA Oncol, 2020,6(6):1-9. DOI: 10.1001/jamaoncol.2020.0409.
[39]	Oxnard GR, Yang JC, Yu H, et al. TATTON: a multi-arm, phase Ⅰb trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer[J]. Ann Oncol, 2020,31(4):507-516. DOI: 10.1016/j.annonc.2020.01.013. doi: 10.1016/j.annonc.2020.01.013 pmid: 32139298
[40]	Oshima Y, Tanimoto T, Yuji K, et al. EGFR-TKI-associated interstitial pneumonitis in nivolumab-treated patients with non-small cell lung cancer[J]. JAMA Oncol, 2018,4(8):1112-1115. DOI: 10.1001/jamaoncol.2017.4526. doi: 10.1001/jamaoncol.2017.4526 pmid: 29327061
[41]	Gibbons DL, Chow LQ, Kim DW, et al. 57O efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): a phase Ⅰ expansion in TKI-naïve patients (pts) with EGFR mutant NSCLC[J]. J Thorac Oncol, 2016,11(4 Suppl):S79-S91. DOI: 10.1016/S1556-0864(16)30171-X.
[42]	Gettinger S, Hellmann MD, Chow LQM, et al. Nivolumab plus erlotinib in patients with EGFR-mutant advanced NSCLC[J]. J Thorac Oncol, 2018,13(9):1363-1372. DOI: 10.1016/j.jtho.2018.05.015. doi: 10.1016/j.jtho.2018.05.015 pmid: 29802888
[43]	Rangachari D, VanderLaan PA, Shea M, et al. Correlation between classic driver oncogene mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% expression in lung adenocarcinoma[J]. J Thorac Oncol, 2017,12(5):878-883. DOI: 10.1016/j.jtho.2016.12.026. doi: 10.1016/j.jtho.2016.12.026 pmid: 28104537
[44]	Mhanna L, Guibert N, Milia J, et al. When to consider immune checkpoint inhibitors in oncogene-driven non-small cell lung cancer[J]. Curr Treat Options Oncol, 2019,20(7):60. DOI: 10.1007/s11864-019-0652-3. doi: 10.1007/s11864-019-0652-3 pmid: 31172347